Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Carolyn Yung Ho, M.D.

Co-Author

This page shows the publications co-authored by Carolyn Ho and Neal Lakdawala.
Connection Strength

5.971
  1. Associations Between Female Sex, Sarcomere Variants, and Clinical Outcomes in Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2021 02; 14(1):e003062.
    View in: PubMed
    Score: 0.909
  2. Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. Circ Cardiovasc Genet. 2012 Oct 01; 5(5):503-10.
    View in: PubMed
    Score: 0.513
  3. Genetic testing for dilated cardiomyopathy in clinical practice. J Card Fail. 2012 Apr; 18(4):296-303.
    View in: PubMed
    Score: 0.493
  4. Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. Am J Cardiol. 2011 Dec 01; 108(11):1606-13.
    View in: PubMed
    Score: 0.480
  5. Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. J Am Coll Cardiol. 2010 Jan 26; 55(4):320-9.
    View in: PubMed
    Score: 0.428
  6. Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. Eur Heart J. 2021 10 07; 42(38):3932-3944.
    View in: PubMed
    Score: 0.241
  7. Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021 10; 27(10):1818-1824.
    View in: PubMed
    Score: 0.240
  8. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020 06 02; 75(21):2649-2660.
    View in: PubMed
    Score: 0.219
  9. Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol. 2020 01 01; 5(1):83-91.
    View in: PubMed
    Score: 0.213
  10. The uptake of family screening in hypertrophic cardiomyopathy and an online video intervention to facilitate family communication. Mol Genet Genomic Med. 2019 11; 7(11):e940.
    View in: PubMed
    Score: 0.208
  11. Response by Ho et al to Letter Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". Circulation. 2019 03 19; 139(12):1559-1560.
    View in: PubMed
    Score: 0.202
  12. Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers. Eur Heart J Cardiovasc Imaging. 2018 10 01; 19(10):1109-1116.
    View in: PubMed
    Score: 0.195
  13. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018 10 02; 138(14):1387-1398.
    View in: PubMed
    Score: 0.194
  14. Role of Genetic Testing in Inherited Cardiovascular Disease: A Review. JAMA Cardiol. 2017 10 01; 2(10):1153-1160.
    View in: PubMed
    Score: 0.182
  15. Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. J Am Coll Cardiol. 2016 11 29; 68(21):2299-2307.
    View in: PubMed
    Score: 0.172
  16. Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers. Heart. 2016 Nov 15; 102(22):1805-1812.
    View in: PubMed
    Score: 0.169
  17. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC Heart Fail. 2015 Feb; 3(2):180-8.
    View in: PubMed
    Score: 0.149
  18. Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy. Circ Cardiovasc Genet. 2013 Jun; 6(3):230-7.
    View in: PubMed
    Score: 0.135
  19. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013 May 01; 6(3):415-22.
    View in: PubMed
    Score: 0.133
  20. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010 Aug 05; 363(6):552-63.
    View in: PubMed
    Score: 0.111
  21. Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation. Genet Med. 2021 07; 23(7):1281-1287.
    View in: PubMed
    Score: 0.058
  22. Discordant clinical features of identical hypertrophic cardiomyopathy twins. Proc Natl Acad Sci U S A. 2021 03 09; 118(10).
    View in: PubMed
    Score: 0.058
  23. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020 09 12; 396(10253):759-769.
    View in: PubMed
    Score: 0.056
  24. Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2020 10; 13(5):396-405.
    View in: PubMed
    Score: 0.056
  25. Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry. Circulation. 2020 04 28; 141(17):1371-1383.
    View in: PubMed
    Score: 0.054
  26. A Comparison of Whole Genome Sequencing to Multigene Panel Testing in Hypertrophic Cardiomyopathy Patients. Circ Cardiovasc Genet. 2017 Oct; 10(5).
    View in: PubMed
    Score: 0.046
  27. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012 Feb 16; 366(7):619-28.
    View in: PubMed
    Score: 0.031
  28. A novel custom resequencing array for dilated cardiomyopathy. Genet Med. 2010 May; 12(5):268-78.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.